vs

Side-by-side financial comparison of Braemar Hotels & Resorts Inc. (BHR) and Esperion Therapeutics, Inc. (ESPR). Click either name above to swap in a different company.

Esperion Therapeutics, Inc. is the larger business by last-quarter revenue ($168.4M vs $165.6M, roughly 1.0× Braemar Hotels & Resorts Inc.). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs -4.5%). Over the past eight quarters, Esperion Therapeutics, Inc.'s revenue compounded faster (10.6% CAGR vs -13.1%).

Braemar Hotels & Resorts Inc. is a publicly traded real estate investment trust focused on owning and operating premium luxury hotel and resort properties primarily across the United States. It caters to upscale leisure travelers, corporate event planners, and premium business guests, generating revenue via accommodation bookings, on-site amenities, and event hosting.

Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.

BHR vs ESPR — Head-to-Head

Bigger by revenue
ESPR
ESPR
1.0× larger
ESPR
$168.4M
$165.6M
BHR
Growing faster (revenue YoY)
ESPR
ESPR
+148.2% gap
ESPR
143.7%
-4.5%
BHR
Faster 2-yr revenue CAGR
ESPR
ESPR
Annualised
ESPR
10.6%
-13.1%
BHR

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
BHR
BHR
ESPR
ESPR
Revenue
$165.6M
$168.4M
Net Profit
$-33.6M
Gross Margin
Operating Margin
-7.3%
50.6%
Net Margin
-20.3%
Revenue YoY
-4.5%
143.7%
Net Profit YoY
-80.1%
EPS (diluted)
$-0.67
$0.32

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BHR
BHR
ESPR
ESPR
Q4 25
$165.6M
$168.4M
Q3 25
$143.6M
$87.3M
Q2 25
$179.1M
$82.4M
Q1 25
$215.8M
$65.0M
Q4 24
$173.3M
$69.1M
Q3 24
$148.4M
$51.6M
Q2 24
$187.6M
$73.8M
Q1 24
$219.1M
$137.7M
Net Profit
BHR
BHR
ESPR
ESPR
Q4 25
$-33.6M
Q3 25
$5.7M
$-31.3M
Q2 25
$-5.5M
$-12.7M
Q1 25
$11.0M
$-40.5M
Q4 24
$-18.7M
Q3 24
$12.6M
$-29.5M
Q2 24
$-11.6M
$-61.9M
Q1 24
$15.9M
$61.0M
Operating Margin
BHR
BHR
ESPR
ESPR
Q4 25
-7.3%
50.6%
Q3 25
20.8%
-11.4%
Q2 25
10.0%
8.6%
Q1 25
17.0%
-34.0%
Q4 24
2.2%
-6.4%
Q3 24
47.4%
-31.0%
Q2 24
6.5%
3.5%
Q1 24
19.4%
52.5%
Net Margin
BHR
BHR
ESPR
ESPR
Q4 25
-20.3%
Q3 25
4.0%
-35.9%
Q2 25
-3.1%
-15.4%
Q1 25
5.1%
-62.2%
Q4 24
-10.8%
Q3 24
8.5%
-57.2%
Q2 24
-6.2%
-83.9%
Q1 24
7.3%
44.3%
EPS (diluted)
BHR
BHR
ESPR
ESPR
Q4 25
$-0.67
$0.32
Q3 25
$-0.12
$-0.16
Q2 25
$-0.24
$-0.06
Q1 25
$-0.04
$-0.21
Q4 24
$-0.47
$-0.14
Q3 24
$-0.02
$-0.15
Q2 24
$-0.33
$-0.33
Q1 24
$0.05
$0.34

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BHR
BHR
ESPR
ESPR
Cash + ST InvestmentsLiquidity on hand
$124.4M
$167.9M
Total DebtLower is stronger
$1.1B
Stockholders' EquityBook value
$138.7M
$-302.0M
Total Assets
$1.9B
$465.9M
Debt / EquityLower = less leverage
7.96×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BHR
BHR
ESPR
ESPR
Q4 25
$124.4M
$167.9M
Q3 25
$116.3M
$92.4M
Q2 25
$80.2M
$86.1M
Q1 25
$81.7M
$114.6M
Q4 24
$135.5M
$144.8M
Q3 24
$168.7M
$144.7M
Q2 24
$114.6M
$189.3M
Q1 24
$137.1M
$226.6M
Total Debt
BHR
BHR
ESPR
ESPR
Q4 25
$1.1B
Q3 25
$1.2B
Q2 25
$1.2B
Q1 25
$1.2B
Q4 24
$1.2B
Q3 24
$1.2B
Q2 24
$1.1B
Q1 24
$1.2B
Stockholders' Equity
BHR
BHR
ESPR
ESPR
Q4 25
$138.7M
$-302.0M
Q3 25
$211.9M
$-451.4M
Q2 25
$225.1M
$-433.5M
Q1 25
$238.9M
$-426.2M
Q4 24
$240.7M
$-388.7M
Q3 24
$276.9M
$-370.2M
Q2 24
$282.3M
$-344.2M
Q1 24
$307.3M
$-294.3M
Total Assets
BHR
BHR
ESPR
ESPR
Q4 25
$1.9B
$465.9M
Q3 25
$2.0B
$364.0M
Q2 25
$2.1B
$347.1M
Q1 25
$2.1B
$324.0M
Q4 24
$2.1B
$343.8M
Q3 24
$2.2B
$314.1M
Q2 24
$2.2B
$352.3M
Q1 24
$2.3B
$373.1M
Debt / Equity
BHR
BHR
ESPR
ESPR
Q4 25
7.96×
Q3 25
5.50×
Q2 25
5.38×
Q1 25
5.03×
Q4 24
5.03×
Q3 24
4.36×
Q2 24
4.00×
Q1 24
3.98×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BHR
BHR
ESPR
ESPR
Operating Cash FlowLast quarter
$40.8M
$45.2M
Free Cash FlowOCF − Capex
$-37.1M
FCF MarginFCF / Revenue
-22.4%
Capex IntensityCapex / Revenue
47.1%
0.0%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-59.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BHR
BHR
ESPR
ESPR
Q4 25
$40.8M
$45.2M
Q3 25
$-5.8M
$-4.3M
Q2 25
$23.0M
$-31.4M
Q1 25
$15.1M
$-22.6M
Q4 24
$66.8M
$-35.0M
Q3 24
$9.0K
$-35.3M
Q2 24
$24.1M
$-7.2M
Q1 24
$36.0M
$53.8M
Free Cash Flow
BHR
BHR
ESPR
ESPR
Q4 25
$-37.1M
Q3 25
$-27.3M
Q2 25
$5.3M
Q1 25
$-159.0K
Q4 24
$-3.8M
Q3 24
$-15.6M
$-35.5M
Q2 24
$8.2M
$-7.3M
Q1 24
$12.7M
$53.8M
FCF Margin
BHR
BHR
ESPR
ESPR
Q4 25
-22.4%
Q3 25
-19.0%
Q2 25
3.0%
Q1 25
-0.1%
Q4 24
-2.2%
Q3 24
-10.5%
-68.7%
Q2 24
4.4%
-9.9%
Q1 24
5.8%
39.0%
Capex Intensity
BHR
BHR
ESPR
ESPR
Q4 25
47.1%
0.0%
Q3 25
15.0%
0.0%
Q2 25
9.9%
0.0%
Q1 25
7.1%
0.0%
Q4 24
40.7%
0.0%
Q3 24
10.5%
0.3%
Q2 24
8.5%
0.1%
Q1 24
10.7%
0.1%
Cash Conversion
BHR
BHR
ESPR
ESPR
Q4 25
Q3 25
-1.00×
Q2 25
Q1 25
1.38×
Q4 24
Q3 24
0.00×
Q2 24
Q1 24
2.26×
0.88×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BHR
BHR

Occupancy$97.4M59%
Food And Beverage$45.5M28%
Hotel Other$22.6M14%

ESPR
ESPR

Collaboration Revenue$124.7M74%
Products$43.7M26%

Related Comparisons